Elvira Buxó

Supplementary Table 3 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer

Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Susana Graciela Kalko, Pedro Luis Fernández et autres

PDF file - 45K

Supplementary Table 1 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer

Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Susana Graciela Kalko, Pedro Luis Fernández et autres

PDF file - 189K

Supplementary Table 1 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer

Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Susana Graciela Kalko, Pedro Luis Fernández et autres

PDF file - 189K

Supplementary Table Legends 1-3 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer

Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Susana Graciela Kalko, Pedro Luis Fernández et autres

PDF file - 44K

Data from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer

Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Susana Graciela Kalko, Pedro Luis Fernández et autres

Abstract Docetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-resistant prostate cancer (CRPC). However, most patients eventually develop resistance to this treatment. In this study, we aimed to identify key molecular genes and networks associated with docetaxel resistance in two models …

es (code pays fourni par la source)

Supplementary Table 2 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer

Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Susana Graciela Kalko, Pedro Luis Fernández et autres

PDF file - 32K

Data from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer

Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Susana Graciela Kalko, Pedro Luis Fernández et autres

Abstract Docetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-resistant prostate cancer (CRPC). However, most patients eventually develop resistance to this treatment. In this study, we aimed to identify key molecular genes and networks associated with docetaxel resistance in two models …

es (code pays fourni par la source)

Supplementary Table 2 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer

Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Susana Graciela Kalko, Pedro Luis Fernández et autres

PDF file - 32K

Supplementary Table Legends 1-3 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer

Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Susana Graciela Kalko, Pedro Luis Fernández et autres

PDF file - 44K

Supplementary Table 3 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer

Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Susana Graciela Kalko, Pedro Luis Fernández et autres

PDF file - 45K

Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study

Federico Longo, Mónica Jorge, Ricardo Yayá, Ana Fernández Montés et autres

Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, retrospective study carried out in 20 Spanish hospitals, in patients who started ramucirumab treatment between December 2015 …

es (code pays fourni par la source)

1545P DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts)

Helena Verdaguer, Montse Bacardit Guardiola, Francesco Mattia Mancuso, D.A. Acosta Eyzaguirre et autres

es (code pays fourni par la source)